(Q42085642)

English

Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method

scientific article published on September 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method (English)

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Patricia A. Bradford

1

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

author name string

Peter J Petersen

2

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Mairead Young

3

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

C Hal Jones

4

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Mark Tischler

5

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

John O'Connell

6

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

language of work or name

0 references

publication date

1 September 2005

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

49

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

9

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

3903-3909

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

In vitro activities of tigecycline against the Bacteroides fragilis group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195415

30 May 2018

Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195415

30 May 2018

Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195415

30 May 2018

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195415

30 May 2018

Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195415

30 May 2018

In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195415

30 May 2018

In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195415

30 May 2018

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195415

30 May 2018

In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195415

30 May 2018

Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195415

17 August 2018

Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195415

17 August 2018

Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195415

17 August 2018

In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline

1 reference

https://pubmed.ncbi.nlm.nih.gov/16127069

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.49.9.3903-3909.2005

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42085642&oldid=1933505030"